ACT Share Price

Open 212.00 Change Price %
High 212.00 1 Day -4.85 -2.30
Low 206.20 1 Week -8.45 -3.94
Close 206.20 1 Month 6.60 3.31
Volume 1442 1 Year 87.35 73.50
52 Week High 218.25
52 Week Low 111.00
ACT Important Levels
Resistance 2 211.58
Resistance 1 209.36
Pivot 208.13
Support 1 203.04
Support 2 200.82
ETR Germany Most Active Stocks
CBK 8.06 2.81%
CBK 8.06 2.81%
DBK 18.06 2.03%
DBK 18.06 2.03%
DTE 16.43 1.29%
DTE 16.43 1.29%
DTE 16.43 1.29%
DTE 16.43 1.29%
DTE 16.43 1.29%
EOAN 7.36 0.68%
More..
ETR Germany Top Gainers Stocks
S9H 0.16 45.45%
I7N 0.58 13.73%
5M71 39.00 13.70%
AWM 82.90 11.57%
TGT 0.54 8.00%
TGT 0.54 8.00%
TGT 0.54 8.00%
SNG 7.17 7.01%
SNG 7.17 7.01%
BEO 3.38 6.96%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
NK2A 0.28 -20.00%
TIN 0.41 -12.77%
TIN 0.41 -12.77%
TIN 0.41 -12.77%
ULC 2.50 -10.39%
More..

Actelion Ltd (ETR: ACT)

ACT Technical Analysis 5
As on 20th Jan 2017 ACT Share Price closed @ 206.20 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 150.46 & Strong Buy for SHORT-TERM with Stoploss of 183.28 we also expect STOCK to react on Following IMPORTANT LEVELS.
ACT Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
ACT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.actelion.com
ACT Address
ACT
Gewerberstrasse 16
Allschwil, 4123
Switzerland
Phone: 41 61 565 65 65
Fax: 41 61 565 65 00
ACT Latest News
Interactive Technical Analysis Chart Actelion Ltd ( ACT ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Actelion Ltd
ACT Business Profile
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for diseases with unmet medical needs. Its products include Tracleer, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension (PAH), a chronic and life-threatening disorder that severely compromises the functions of the lungs and heart; Opsumit, an orally available endothelin receptor antagonist; and Valchlor, a chemotherapeutic agent for the treatment of mycosis fungoides, a common type of cutaneous T-cell lymphoma. The company also provides Veletri, a formulation of epoprostenol for the treatment of PAH; Ventavis, an inhaled formulation of iloprost for the treatment of PAH; and Zavesca, an oral treatment for patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is unsuitable. Actelion Ltd markets its products in Switzerland, the United States, Japan, China, Russia, and Mexico. The company was founded in 1997 and is headquartered in Allschwil, Switzerland.